Biophytis (EPA:ALBPS) | WebDisclosure

REGULATED PRESS RELEASE

published on 01/21/2025 at 07:00, 1 year 8 months ago

Biophytis et AskHelpU signent un accord de co-développement dans les maladies rares neuromusculaires en Chine
Biophy's et AskHelpU signent un accord de co-développement dans les maladies rares neuromusculaires en Chine. Analyse de l'efficacité du candidat-médicament BIO101 de Biophytis dans la SLA

Maladies Rares Biophy's SLA Co-développement AskHelpU
REGULATED PRESS RELEASE

published on 01/21/2025 at 07:00, 1 year 8 months ago

Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China
Biophy's and AskHelpU sign a co-development agreement for rare neuromuscular diseases in China. The agreement aims to evaluate BIO101's efficacy in ALS, potentially offering a major therapeutic solution for patients

Biophy's ALS AskHelpU Co-development Agreement Neuromuscular Diseases
BRIEF

published on 01/14/2025 at 07:05, 1 year 8 months ago

Biophytis en Négociation Exclusive pour Licencier BIO101 en Chine

Biophytis Négociation Exclusive Chine Pharmaceutique BIO101
BRIEF

published on 01/14/2025 at 07:05, 1 year 8 months ago

Biophytis Enters Exclusive Negotiations for BIO101 in China

Biophytis Age-related Diseases BIO101 Pharmaceutical Partnership China Licensing
REGULATED PRESS RELEASE

published on 01/14/2025 at 07:00, 1 year 8 months ago

Biophytis entre en négociation exclusive avec une société pharmaceutique chinoise pour licencier BIO101
Biophytis entre en négociation exclusive avec une société pharmaceutique chinoise pour licencier BIO101. L'objectif est de co-développer et commercialiser le traitement en Chine

Biophytis Négociation Exclusive BIO101 Co-développement Société Pharmaceutique Chinoise
REGULATED PRESS RELEASE

published on 01/14/2025 at 07:00, 1 year 8 months ago

Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101
Biophytis enters exclusive negotiations with a Chinese pharmaceutical company to license BIO101 for viral respiratory infections, sarcopenia, and obesity. The potential partnership aims to develop and commercialize the drug in China's growing pharmaceutical market

Biophytis Exclusive Negotiations Chinese Pharmaceutical Company BIO101 License Viral Respiratory Infections
BRIEF

published on 01/08/2025 at 07:05, 1 year 8 months ago

Biophytis obtient des financements pour son programme d'obésité

Investissement Biophytis Refinancement BIO101 Obésité
BRIEF

published on 01/08/2025 at 07:05, 1 year 8 months ago

Biophytis Secures €8.6 Million for Obesity Program

Clinical Development Debt Conversion Obesity Program Biophytis Financing New Investors
REGULATED PRESS RELEASE

published on 01/08/2025 at 07:00, 1 year 8 months ago

Biophytis annonce un nouvel apport en cash et une conversion de dettes pouvant atteindre 8,6 M€ pour financer son programme dans l’obésité
Biophytis annonce un nouvel apport en cash de 2,5 M€ et une conversion de dettes jusqu'à 6,1 M€ pour financer son programme dans l'obésité. Opération de refinancement de 8,6 M€ pour consolider sa structure financière et lancer l'étude de phase 2 OBA aux États-Unis

Biophytis Financement Développement Clinique Opération Financière Obésité
REGULATED PRESS RELEASE

published on 01/08/2025 at 07:00, 1 year 8 months ago

Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 million to Finance the Obesity Program
Biophytis announces new cash contribution and debt conversion totaling €8.6 million to finance obesity program. Strategic financial transaction strengthens company's financial structure for future development

Biophytis Financial Transaction Debt Conversion Obesity Program Cash Contribution

Published on 09/23/2026 at 22:00, 8 minutes ago

Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 3 hours 43 minutes ago

Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 6 hours 26 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 7 hours 37 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 7 hours 38 minutes ago

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

View all ACCESSWIRE

Published on 09/23/2026 at 19:51, 2 hours 17 minutes ago

LIGHTON: LightOn renouvelle son financement obligataire auprès des mêmes partenaires financiers pour un montant nominal maximum de 4 millions d’euros, et étend ainsi son horizon de trésorerie
Published on 09/23/2026 at 19:51, 2 hours 17 minutes ago

LIGHTON: LightOn renews its bond financing with the same financial partners for a maximum nominal amount of €4 million, and thus extends its cash flow horizon
Published on 09/23/2026 at 19:30, 2 hours 38 minutes ago

EUROPLASMA: Valdunes Industries et Saarstahl Ascoval s’associent pour développer une nouvelle génération de « roues vertes »
Published on 09/23/2026 at 18:05, 4 hours 3 minutes ago

XPRIZE Wildfire Awards $4.55M to Innovators Advancing Wildfire Detection and Response
Published on 09/23/2026 at 18:00, 4 hours 8 minutes ago

ARVERNE GROUP: Release of the 2026 half-year financial report

View all EQS

Published on 09/23/2026 at 19:46, 2 hours 22 minutes ago

SFPI GROUP: half year 2026 results
Published on 09/23/2026 at 19:46, 2 hours 22 minutes ago

SFPI GROUP: publication des résultats semestriels 2026
Published on 09/23/2026 at 19:14, 2 hours 54 minutes ago

Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 19:14, 2 hours 54 minutes ago

Performance robuste des Investissements, poursuite du déploiement de la stratégie
Published on 09/23/2026 at 18:00, 4 hours 8 minutes ago

CIS : H1 2026 results.

View all LES ECHOS COMFI WIRE

News